首页 | 本学科首页   官方微博 | 高级检索  
     


Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network
Authors:Jeanna Wallenta Law  Debanjali Mitra  Henry G. Kaplan  Tamuno Alfred  Adam M. Brufsky  Birol Emir  Haley McCracken  Xianchen Liu  Ronda G. Broome  Chenan Zhang  Caroline DiCristo  Connie Chen
Affiliation:1.Syapse, San Francisco, CA 94107, USA; (H.M.); (R.G.B.); (C.Z.);2.Pfizer Inc., New York, NY 10017, USA; (D.M.); (T.A.); (B.E.); (X.L.); (C.D.); (C.C.);3.Swedish Cancer Institute, Seattle, WA 98104, USA;4.Comprehensive Breast Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA;
Abstract:
This retrospective single-arm study assessed real-world treatment patterns and clinical outcomes in patients with hormone receptor—positive/human epidermal growth factor receptor 2—negative (HR+/HER2−) advanced/metastatic breast cancer (A/MBC) who received palbociclib plus an aromatase inhibitor as first-line therapy in US community health systems. Using electronic health records from the Syapse Learning Health Network, 242 patients were identified as having received first-line palbociclib plus an aromatase inhibitor between 3 February 2015, and 31 July 2019 (data cutoff 1 February 2020) resulting in a minimum potential 6-month follow-up period. In total, 56.6% of patients had de novo A/MBC at initial breast cancer diagnosis, 50.8% had bone-only disease, and 32.2% had visceral disease. Median follow-up was 22.4 months. Disease progression (26.4%) and intolerance/toxicity (14.9%) were the main reasons for treatment discontinuation. The median (95% CI) real-world progression-free survival was 31.7 (27.9—not estimable (NE)) months and 2-year estimated overall survival (OS) rate was 78.0%. In total, 25.6% of patients died; however, OS data are limited by the small population size and insufficient follow-up time. These real-world effectiveness outcomes complement findings from other real-world studies and randomized controlled trials and support palbociclib plus an aromatase inhibitor as first-line therapy for HR+/HER2− A/MBC.
Keywords:HR+/HER2−  , metastatic breast cancer, palbociclib, aromatase inhibitor, real-world data
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号